KWM
CPRX

Keebeck Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Keebeck Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Sell
10,763
-14,413
-57% -$425K 0.03% 345
2026
Q1 		$623K Buy
25,176
+2,149
+9% +$51.2K 0.07% 204
2025
Q4 		$537K Buy
23,027
+5,245
+29% +$117K 0.06% 207
2025
Q3 		$350K Sell
17,782
-2,645
-13% -$54.4K 0.04% 277
2025
Q2 		$443K Buy
20,427
+11,127
+120% +$263K 0.06% 220
2025
Q1 		$226K Buy
+9,300
New +$209K 0.03% 253

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Keebeck Wealth Management's CPRX Position: Q2 2026 in Review

Keebeck Wealth Management reduced its Catalyst Pharmaceutical (CPRX) stake by 57% in Q2 2026, selling an estimated $425K and leaving 10,763 shares worth $338K. The position accounts for 0.03% of the portfolio, ranked #345.

Keebeck Wealth Management first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $623K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Keebeck Wealth Management held 10,763 shares of Catalyst Pharmaceutical worth $338K as of Q2 2026.
  • Keebeck Wealth Management sold 14,413 Catalyst Pharmaceutical shares in Q2 2026, an estimated $425K.
  • Catalyst Pharmaceutical made up 0.03% of Keebeck Wealth Management's portfolio in Q2 2026, its #345 holding.
  • Keebeck Wealth Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • Keebeck Wealth Management's Catalyst Pharmaceutical position peaked at $623K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Keebeck Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.